How to Reconstitute Cagrilintide

Cagrilintide is a long-acting amylin receptor agonist developed as a once-weekly subcutaneous agent, and it is supplied to laboratories as a lyophilised powder that must be brought into solution before use. Synonyms in the literature include cagrilintide and, in fixed-dose combination with semaglutide, CagriSema [4][9]. The evidence block for this page does not give a sequence, molecular formula or molecular weight, so none are stated here. Identifiers that do appear are study-level: the compound has been tested in humans before and is not yet prescribable [1].

The work on this compound centres on the amylin receptor, a heterodimer of the calcitonin receptor (Calcr) and a receptor-activity-modifying protein, and on Calcr-expressing neuronal populations in the caudal brainstem [3].

Research Studies

Cagrilintide and Calcr-expressing dorsal vagal complex neurons in rat, mouse and macaque

A cross-species transcriptomic atlas of over 530,000 cells, comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling in the rat dorsal vagal complex (DVC), was generated to identify mediators of cagrilintide action [3]. Cagrilintide was reported to regulate two conserved Calcr-expressing DVC neuronal populations. Acute cagrilintide treatment altered gene expression in area postrema Calcr/Ramp3 neurons, but chemogenetic activation of those neurons in rats did not affect long-term food intake or body weight. Long-term cagrilintide treatment in rats upregulated a separate population, and this finding is animal-only [3].

Cagrilintide and food intake and appetite in people with overweight or obesity

A clinical study is testing cagrilintide to understand how it affects food intake and appetite in people with overweight or obesity. Participants receive either cagrilintide or placebo, assigned by chance, and the study lasts about 30 weeks [8]. This is a human study; results are not reported in the evidence block.

Cagrilintide and tolerability in participants not tolerating GLP-1 receptor agonists

A clinical study is examining the safety of cagrilintide compared with placebo in people who do not tolerate marketed glucagon-like peptide-1 (GLP-1) therapies and who live with overweight or obesity. Participants receive cagrilintide or placebo by chance, and the study lasts about 8 months [5]. This is a human study; results are not reported in the evidence block.

Cagrilintide and pharmacokinetics in renal or hepatic impairment

Two studies assessed the effects of renal or hepatic impairment on pharmacokinetics, safety and tolerability following single doses of cagrilintide. Adult participants were categorised into four groups on the basis of renal or hepatic function (normal function and mild, moderate or severe impairment) and received a single dose of cagrilintide 0.6 or 0.9 [4]. The evidence block does not report the outcome values.

Cagrilintide and comparison of two injectable versions in people with excess body weight

A clinical study compared two different versions of injectable cagrilintide and placebo in people with excess body weight. Participants received cagrilintide, the active study medicine, or placebo, by chance, and were in the study for about 9 months [1]. This is a human study; results are not reported in the evidence block.

Cagrilintide and blood levels of two versions in adults with excess body weight

A clinical study compared two different versions of cagrilintide to see how they work in people living with excess body weight. Participants received either cagrilintide B or cagrilintide D injections, assigned by chance, and were in the study for about 14 weeks [6]. A separate study compared blood levels of cagrilintide after multiple doses of different versions in adults with overweight or obesity; participants received version D or version B by chance, and were in the study for about 6 months [7]. These are human studies; results are not reported in the evidence block.

Cagrilintide and comparative effectiveness in overweight and obesity

A network meta-analysis of randomised clinical trials examined the comparative efficacy and safety of tirzepatide, semaglutide, cagrilintide and their combination (CagriSema) in the management of overweight and obesity, noting that no direct head-to-head studies had compared all advanced anti-obesity medications [2]. The evidence block does not report the pooled effect estimates.

Cagrilintide and amylin-based obesity therapy versus placebo

A systematic review and meta-analysis evaluated amylin-based obesity therapy, specifically cagrilintide and CagriSema versus placebo, describing cagrilintide as a once-weekly amylin receptor agonist and CagriSema as its fixed-dose combination with semaglutide [9]. The evidence block does not report the pooled effect estimates.

Cagrilintide-semaglutide and glycaemic control in type 2 diabetes

Two phase 3 studies, REIMAGINE 1 and REIMAGINE 2, assessed cagrilintide-semaglutide (CagriSema), a once-weekly fixed-dose combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with type 2 diabetes. REIMAGINE 1 enrolled adults inadequately controlled on diet and exercise; REIMAGINE 2 compared CagriSema with semaglutide or cagrilintide [10][11]. A further report describes cagrilintide-semaglutide as a new option for patients with type 2 diabetes [12]. These are human studies; the evidence block does not report their outcome values.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight — https://clinicaltrials.gov/study/NCT07745504
• [2] Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials — https://europepmc.org/article/PMC/PMC13239642
• [3] A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance — https://europepmc.org/article/PMC/PMC13303089
• [4] Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide — https://europepmc.org/article/PMC/PMC13356073
• [5] Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — https://clinicaltrials.gov/study/NCT07607587
• [6] A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight — https://clinicaltrials.gov/study/NCT07605052
• [7] A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity — https://clinicaltrials.gov/study/NCT07597018
• [8] A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity — https://clinicaltrials.gov/study/NCT07557953
• [9] Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo — https://europepmc.org/article/PMC/PMC13461105
• [10] Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study — https://pubmed.ncbi.nlm.nih.gov/42251860/
• [11] Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study — https://pubmed.ncbi.nlm.nih.gov/42251859/
• [12] Cagrilintide-semaglutide: a new option for patients with type 2 diabetes — https://pubmed.ncbi.nlm.nih.gov/42251858/